# An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

> **NCT00373659** · PHASE2 · COMPLETED · sponsor: **University of Miami** · enrollment: 40 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab (Lucentis)

## Key facts

- **NCT ID:** NCT00373659
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373659, "An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00373659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*